UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049939
Receipt number R000056877
Scientific Title Evaluation of the Effectiveness of a Smartphone Application for Hay Fever Treatment Assistance in Improving of Subjective Symptoms of Hay Fever: A Prospective, Randomized, Controlled Study.
Date of disclosure of the study information 2023/01/14
Last modified on 2023/07/05 14:11:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the effectiveness of a smartphone app for hay fever treatment assistance in improving subjective symptoms of hay fever.

Acronym

Evaluation of the effectiveness of a smartphone app for hay fever treatment assistance in improving hay fever symptoms.

Scientific Title

Evaluation of the Effectiveness of a Smartphone Application for Hay Fever Treatment Assistance in Improving of Subjective Symptoms of Hay Fever: A Prospective, Randomized, Controlled Study.

Scientific Title:Acronym

Evaluation of the Effectiveness of a Smartphone App for Hay Fever Treatment Assistance in Improving of Subjective Symptoms of Hay Fever.

Region

Japan


Condition

Condition

Hay fever

Classification by specialty

Ophthalmology Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In this study, the effectiveness of a smartphone application (ALA01) as a hay fever treatment assistance will be evaluated.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The following items at 4 weeks after the inclusion time point (Day 0)
Hay fever subjective symptom assessment: Nasal symptom score (NSS), Non-nasal symptom score (NNSS), Total symptom score (TSS), and Allergic Conjunctival Quality of Life Questionnaire (JACQLQ) Domain II score2

Key secondary outcomes

The following items at 4 weeks after the inclusion time point (Day 0)
(1) Basic information on research subjects: age, sex, diagnosis, duration of disease, treatment details (drugs used, duration of treatment)
(2) Allergy test results
(3) Medication adherence assessment: Medication adherence scale (MMAS-8)
(4) Medication record
(5) Viewing status of educational contents in the application
(6) Operability evaluation


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Use ALA01 in addition to prescribed hay fever medications.

Interventions/Control_2

Use only prescribed hay fever medications.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients with NSS score between 3 and 10 and NNSS score between 3 and 8 on Day 0.
(2) Patients who can understand and agree to the consent form
(3) Patients who can operate a smart phone
(4) Patients who are 20 years of age or older

Key exclusion criteria

(1) Those who are deemed inappropriate as research subjects by the principal investigator
(2) Those who could not give their consent

Target sample size

66


Research contact person

Name of lead principal investigator

1st name Takenori
Middle name
Last name Inomata

Organization

Juntendo University

Division name

Graduate School of Medicine, Department of Ophthalmology

Zip code

113-8421

Address

2-1-1 Hongo, Building A, 6th floor, Ophthalmology Department, Bunkyo-ku, Tokyo, Japan

TEL

03-5802-1228

Email

tinoma@juntendo.ac.jp


Public contact

Name of contact person

1st name Takenori
Middle name
Last name Inomata

Organization

Juntendo University

Division name

Graduate School of Medicine, Department of Ophthalmology

Zip code

113-8421

Address

2-1-1 Hongo, Building A, 6th floor, Ophthalmology Department, Bunkyo-ku, Tokyo, Japan

TEL

03-5802-1228

Homepage URL


Email

tinoma@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Juntendo University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Independent Ethics Committee of Juntendo University Faculty of Medicine

Address

3-1-3 Hongo, Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan

Tel

03-3814-5672

Email

jcrtc_operation@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 12 Month 16 Day

Date of IRB

2022 Year 12 Month 16 Day

Anticipated trial start date

2023 Year 02 Month 01 Day

Last follow-up date

2023 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 12 Month 28 Day

Last modified on

2023 Year 07 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056877


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name